BCAB Historical PE Ratio Notes

— BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biopharmaceutical company focused on developing novel antibody-based therapeutics for cancer treatment, especially those using its proprietary Conditionally Active Biologics (CAB) technology. CAB antibodies are designed to selectively activate in the tumor microenvironment while remaining inactive in normal tissue, potentially increasing treatment efficacy & safety. As an investor preparing to research BioAtla's historical price-to-earnings (PE) ratio, it's important to recognize that, as a pre-commercial biotech, BCAB's earnings have historically been negative or minimal—reflecting substantial R&D spending without significant revenue or profits. This often means the traditional PE ratio will be either not meaningful (N/M), not calculable, or extremely high during periods of small positive earnings. In biotech, these ratios are less informative than in mature sectors; market participants typically value companies like BioAtla based on clinical progress, data readouts, potential addressable markets, & partnership potential, rather than trailing or even forward earnings. As you review historical charts & tables, be mindful that fluctuations in the PE ratio, or blanks in the data, primarily reflect the realities of a company investing heavily in future breakthroughs rather than established profitability.

On this page we presented the BCAB Historical PE Ratio information for BioAtla' stock. The average BCAB historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BCAB historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BCAB historical PE result, against the recent PE: when this page was posted on 6/1/2026, the most recent closing price for BCAB had been 3.53, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on BCAB or any other given stock, valuation analysis for BCAB can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate BioAtla PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BCAB. Thanks for visiting, and the next time you need to research BCAB Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.